PTPRC and neoplasm: The mice that were intravenously administered DJ4-pretreated AML cells also exhibited a decreased bioluminescent signal, increased survival of 10 and 20 days, and a reduction in the percentage of human CD45 cells in the bone marrow or spleen, indicating a diminished tumor burden (Figure 7 and Figure S8).